))
Precision medicine, NGS, and the quantum leap in biomarkers
Manage episode 456203030 series 3079777
Content provided by pharmaphorum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by pharmaphorum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.
Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent company, and that collaboration’s investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company’s value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions.
That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies’ – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.
252 episodes
Share
